Kymera Therapeutics (NASDAQ:KYMR) Director Sells 4,159 Shares

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Bruce Booth sold 4,159 shares of Kymera Therapeutics stock in a transaction that occurred on Tuesday, April 14th. The stock was sold at an average price of $89.97, for a total value of $374,185.23. Following the completion of the sale, the director directly owned 4,159 shares in the company, valued at approximately $374,185.23. The trade was a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Bruce Booth also recently made the following trade(s):

• On Wednesday, April 15th, Bruce Booth sold 3,135 shares of Kymera Therapeutics stock. The stock was sold at an average price of $90.10, for a total value of $282,463.50.
• On Wednesday, April 15th, Bruce Booth sold 2,200 shares of Kymera Therapeutics stock. The shares were sold at an average price of $89.95, for a total value of $197,890.00.
• On Monday, March 2nd, Bruce Booth sold 81,866 shares of Kymera Therapeutics stock. The stock was sold at an average price of $90.13, for a total value of $7,378,582.58.

Kymera Therapeutics Price Performance

Kymera Therapeutics stock traded down $2.86 during trading hours on Thursday, reaching $86.14. The stock had a trading volume of 554,950 shares, compared to its average volume of 732,626. The business’s 50 day moving average price is $83.69 and its 200-day moving average price is $74.15. Kymera Therapeutics, Inc. has a 52 week low of $24.72 and a 52 week high of $103.00. The company has a market cap of $7.03 billion, a price-to-earnings ratio of -23.41 and a beta of 2.28.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.77) by ($0.20). Kymera Therapeutics had a negative net margin of 794.04% and a negative return on equity of 28.71%. The business had revenue of $2.87 million for the quarter, compared to analysts’ expectations of $14.80 million. During the same quarter in the prior year, the company posted ($0.88) EPS. The business’s revenue for the quarter was down 60.8% on a year-over-year basis. On average, sell-side analysts forecast that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Hedge Funds Weigh In On Kymera Therapeutics

Several large investors have recently modified their holdings of KYMR. Smartleaf Asset Management LLC lifted its stake in Kymera Therapeutics by 382.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock worth $42,000 after purchasing an additional 424 shares in the last quarter. Larson Financial Group LLC grew its stake in shares of Kymera Therapeutics by 81.5% in the third quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock valued at $44,000 after buying an additional 349 shares in the last quarter. Osaic Holdings Inc. raised its holdings in shares of Kymera Therapeutics by 18,050.0% in the 2nd quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock valued at $48,000 after buying an additional 1,083 shares during the period. Bessemer Group Inc. raised its holdings in shares of Kymera Therapeutics by 652.0% in the 3rd quarter. Bessemer Group Inc. now owns 940 shares of the company’s stock valued at $53,000 after buying an additional 815 shares during the period. Finally, Caitong International Asset Management Co. Ltd acquired a new position in Kymera Therapeutics during the 4th quarter worth about $63,000.

Analyst Ratings Changes

Several analysts have commented on the stock. BTIG Research decreased their price objective on shares of Kymera Therapeutics from $138.00 to $134.00 and set a “buy” rating for the company in a research note on Thursday, February 26th. Barclays upped their target price on Kymera Therapeutics to $133.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 27th. B. Riley Financial lifted their price objective on shares of Kymera Therapeutics from $80.00 to $117.00 and gave the company a “buy” rating in a report on Monday, December 22nd. Citigroup upped their target price on Kymera Therapeutics from $110.00 to $120.00 and gave the stock a “buy” rating in a research note on Monday, March 2nd. Finally, Morgan Stanley reissued an “overweight” rating and issued a $123.00 price target on shares of Kymera Therapeutics in a research note on Thursday, February 26th. One research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $118.90.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.